Zacks Investment Research upgraded shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) from a hold rating to a buy rating in a research report report published on Thursday. The firm currently has $1.00 price objective on the stock.
According to Zacks, “Sino Biopharmaceutical Limited researches, develops, produces and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis. Sino Biopharmaceutical Limited is headquartered in Wanchai, Hong Kong. “
SINO BIOPHARMACEUT HKD0.025 (NASDAQ SBMFF) opened at 0.988 on Thursday. SINO BIOPHARMACEUT HKD0.025 has a one year low of $0.64 and a one year high of $0.99. The firm has a market cap of $7.32 billion and a PE ratio of 25.333. The company’s 50-day moving average is $0.90 and its 200 day moving average is $0.83.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with MarketBeat.com's FREE daily email newsletter.